This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SH2 domain | |
|---|---|
| Name | SH2 domain |
| Pfam | PF00017 |
| Interpro | IPR000980 |
| Prosite | PDOC00046 |
SH2 domain The SH2 domain is a conserved protein interaction module found in diverse signaling proteins that mediates recognition of phosphorylated tyrosine residues. It plays central roles in intracellular signal transduction cascades initiated by receptor and non-receptor tyrosine kinases, adapter proteins, and scaffold complexes. SH2-containing proteins participate in processes from immune responses to developmental programs by linking extracellular cues to intracellular effector systems.
SH2 domains were initially characterized in studies of oncogenes and growth factor receptors, with early work implicating proteins such as v-Src, c-Abl, GRB2, SHC1, and PI3K in phosphotyrosine-dependent interactions. Researchers at institutions including Cold Spring Harbor Laboratory, Harvard University, MIT, and University of Cambridge contributed to structural and functional definitions alongside groups at Stanford University and Max Planck Society. Discoveries were reported in venues like Nature (journal), Science (journal), and Cell (journal), shaping models of signal transduction influenced by paradigms from investigators such as Tony Pawson, Bruce Mayer, Tony Hunter, and Mark Lemmon.
SH2 domains are approximately 100 amino acids and adopt a compact folded architecture often resolved by techniques developed at facilities like Brookhaven National Laboratory and European Molecular Biology Laboratory. High-resolution structures solved using methods pioneered at Rosalind Franklin Institute and instruments at Diamond Light Source revealed a central beta-sheet flanked by alpha-helices, forming a conserved phosphotyrosine-binding pocket. Biochemical characterization using assays standardized at laboratories like Cold Spring Harbor Laboratory and EMBL-EBI quantitatively defined affinities and kinetics, with contributions from researchers affiliated with Howard Hughes Medical Institute and National Institutes of Health (NIH). SH2 domains display conserved motifs that coordinate with metal-independent binding and hydrophobic specificity pockets identified by teams at University of California, San Francisco and University of Oxford.
Recognition of phosphotyrosine is central to SH2 function; early peptide-library and mutagenesis studies conducted by groups at Imperial College London and Yale University clarified sequence determinants downstream of phosphotyrosine that confer selectivity. Structural comparisons from labs at European Synchrotron Radiation Facility and Scripps Research delineated the roles of pocket residues and adjacent specificity determinants exploited by proteins such as PLC-gamma, STAT3, Crk, Nck, and Dok1. Quantitative binding measurements performed using surface plasmon resonance at companies like Cytiva and biosensor platforms developed at Biacore provided kinetic parameters used in systems biology models from teams at Institute Pasteur and Weizmann Institute of Science.
SH2-mediated interactions orchestrate pathways downstream of receptors such as EGFR, PDGFR, FGFR, Insulin receptor, and immune receptors including T-cell receptor complex, B-cell receptor complex, and Fc receptors. Adapter and effector proteins containing SH2 modules—examples include SH2B1, CRK, GRAP, SHP2, and SOCS family members—link tyrosine kinase activity to cascades like the MAPK/ERK pathway, PI3K/AKT pathway, JAK/STAT pathway, and cytoskeletal regulators connected to Rho GTPases. Studies from clinical centers such as Mayo Clinic, Johns Hopkins University, and Cleveland Clinic connected aberrant SH2 interactions to phenotypes observed in immune dysregulation, developmental disorders, and cancer progression.
SH2 domain function is regulated by mechanisms described in reports from Cold Spring Harbor Laboratory and European Molecular Biology Laboratory including competitive binding, intramolecular autoinhibition, and modulation by post-translational modifications on neighboring regions. Phosphorylation, ubiquitylation, methylation, and acetylation events cataloged by consortia such as Human Proteome Project and databases maintained at UniProt and PhosphoSitePlus influence accessibility and affinity, with examples in proteins like c-Cbl, SHP1, SHP2, and Vav1. Crosstalk between tyrosine phosphorylation and serine/threonine kinases characterized by investigators at Cold Spring Harbor Laboratory and Broad Institute alters SH2-dependent complex assembly in contexts studied at Memorial Sloan Kettering Cancer Center.
Comparative genomics from projects at Ensembl, NCBI, and UCSC Genome Browser reveal SH2 domains across metazoans, with lineage-specific expansions in vertebrates and distinct repertoires in invertebrates such as Drosophila melanogaster and Caenorhabditis elegans. Evolutionary analyses published by groups at European Bioinformatics Institute and Max Planck Institute for Molecular Genetics trace SH2 family diversification through gene duplication, domain shuffling, and fusion events connecting to proteins in signal transduction networks conserved in Arabidopsis thaliana and other plants studied at The Sainsbury Laboratory. Structural conservation together with sequence variation underpins functional specialization observed in datasets from 1000 Genomes Project and comparative studies from Wellcome Sanger Institute.
Aberrant SH2-mediated interactions are implicated in cancers driven by oncoproteins such as BCR-ABL, HER2, and mutated EGFR alleles; therapeutic strategies developed at pharmaceutical centers including Pfizer, Novartis, Roche, and AstraZeneca target upstream kinases or disrupt SH2-dependent complexes. Small molecules, peptidomimetics, and engineered biologics arising from collaborations with institutions like Dana-Farber Cancer Institute, Genentech, and GlaxoSmithKline have aimed to modulate SH2 interactions to treat malignancies and immune disorders; clinical investigations reported through ClinicalTrials.gov evaluate such approaches. Diagnostic applications leveraging SH2 specificity inform biomarkers used in centers including Mayo Clinic and Memorial Sloan Kettering Cancer Center, with translational research supported by funding agencies such as National Cancer Institute and European Commission.
Category:Protein domains